

Special Issue on
**Multimodality Neuroimaging Studies on Preclinical
Alzheimer's Disease**

CALL FOR PAPERS

The 2015 World Alzheimer Report showed that over 46 million people live with dementia in the world and this number is estimated to increase to 131.5 million by 2050. Apart from disability, dementia also brings a huge economic impact. Alzheimer's disease (AD), characterized by memory or other cognitive domain impairments, is the most common type of dementia. Current anti-amyloid approaches to prevent, delay, or treat the AD are not effective for patients with mild to moderate AD. This might be due to the fact that the disease has become too late stage to treat. Fortunately, there is considerable evidence that brain amyloidopathy has been shown to occur several years before the onset of clinical AD. Thus, AD can be considered as a continuum and divided into three stages: (1) the preclinical stage of AD, (2) mild cognitive impairment (MCI) due to AD, and (3) dementia due to AD. The preclinical stage of AD, which may offer the best chance of therapeutic success, has become a major research focus. As such, the key is to identify the patients at the preclinical stage of AD. With development of neuroimaging research, it is now possible to identify AD even at the preclinical stage before the occurrence of the first clinical symptoms.

This special issue is intended to present and discuss the application of multimodality neuroimaging to the preclinical stage of AD. The objective of this issue is to examine the impairment of brain structure and function. In addition, identification of biomarkers, which are able to detect people in the preclinical stage of AD, becomes of crucial importance. We invite investigators to submit original research articles and reviews to this special issue.

Potential topics include but are not limited to the following:

- ▶ Structural MRI study on the preclinical stage of AD
- ▶ Functional MRI (resting state or task state) study on the preclinical stage of AD
- ▶ Diffusion tensor imaging (DTI) study on the preclinical stage of AD
- ▶ Molecular neuroimaging with PET or SPECT study on the preclinical stage of AD
- ▶ At least 2 modalities of neuroimaging including structural MRI, functional MRI, diffusion tensor imaging, or molecular neuroimaging study in the preclinical stage of AD

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/bn/mnp/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Ying Han, Capital Medical University,
Beijing, China
sophiehanying@gmail.com

Guest Editors

Yue Xing, University of Nottingham,
Nottingham, UK
yue.xing@nottingham.ac.uk

Hwee L. Lee, German Center for
Neurodegenerative Disease, Bonn,
Germany
hwee-ling.lee@dzne.de

Jiang He, University of Virginia,
Charlottesville, USA
jh6qv@virginia.edu

Submission Deadline

Friday, 19 January 2018

Publication Date

June 2018